A rejected cannabis consignment is a batch that has already cleared customs in the destination country and then failed the importer's own release testing or documentation review. The flower is legally in the market, physically inside a licensed warehouse you can't enter, and it can't be sold. From that point you have three routes: investigate and re-release the batch, destroy it in the destination market, or bring it back to Canada. Each route carries a different timeline, a different permit chain, and a different answer to the question of who absorbs the loss.
This is not a recall. A recall pulls product that already reached pharmacies or patients, and it's covered by its own reporting duties under the Cannabis Act. A rejection happens earlier, at in-market release, before a single gram moves to a dispensing pharmacy. The distinction matters commercially, because a rejection is a private contract problem first and a regulatory problem second.
What follows is how the three routes work in Germany and Australia, what Health Canada permits on the return leg, and the checks that keep a batch out of this position. If you're comparing what each destination requires before a shipment moves, our guide to cannabis import requirements in Germany, Australia and Israel covers the permit chain in detail.
Why importers reject Canadian cannabis batches
Canada and the European Union have no mutual recognition agreement covering cannabis. Every batch landing in the EU is retested by a GMP-certified laboratory in the destination market, and a Qualified Person there certifies it only after the goods have physically arrived and cleared customs. That sequence is what makes a rejection expensive. The failure surfaces thousands of kilometres from your facility, on someone else's analytical methods, with your inventory already committed.
Most rejections trace back to a short list of causes:
- Microbiological counts above the pharmacopoeial limits the importer applies, which is the most common finding on untreated flower.
- Water activity or moisture drift, where product that left Montreal in specification arrives outside it after a slow transit or a warm dwell at the port.
- Potency variance, where the in-market retest returns a THC figure outside the tolerance written into the specification, so the certificate of analysis no longer describes the goods.
- Contaminant panels that are wider in the destination than in Canada, typically covering pesticide actives or heavy metals your domestic panel didn't screen for.
- Documentation mismatches, where batch numbers fail to reconcile across the COA, the batch record and the label.
That last category is the most avoidable and the least defensible. A quality manager who finds two batch identifiers for one pallet stops the release and asks questions about everything else in the file. Our guide to what importers verify in batch traceability records sets out the five records that get pulled first.
An out-of-specification result is not always a quality failure
Two accredited laboratories running different sample preparations on the same homogenised batch can report potency several percentage points apart. Microbial methods differ too, and so do sampling plans. The question that decides the outcome isn't whose laboratory is better. It's whether your specification names the method, the sampling plan and the acceptable tolerance. When the agreement is silent, the importer's number becomes the operative number by default, and your Canadian COA has no standing in the dispute.
Where the batch sits and who owns the problem
Rejected product doesn't come home on its own. In Australia, medicinal cannabis imported for the unapproved-access pathways has to sit in a warehouse or secured area under the importer's direct control until the goods are approved for supply. Conformity with TGO 93 is the sponsor's legal responsibility there, not yours. The Therapeutic Goods Administration also runs random and targeted TGO 93 compliance audits, so a batch can be challenged after it clears the importer's own release. In Germany, the consignment stays with the holder of the import and manufacturing authorisation until a Qualified Person releases it under EU-GMP rules, with narcotic-control oversight sitting at BfArM. We break that step down in our guide to EU QP batch release for Canadian LPs.
Either way, your flower is in a licensed facility abroad, accruing storage charges, and you're a supplier making requests rather than an owner giving instructions. That asymmetry is the reason the commercial terms matter more than the technical argument.
Incoterms decide who carries risk in transit. They don't decide conformity, and exporters conflate the two constantly. Our breakdown of Incoterms for cannabis exports covers the transit side. Conformity is settled by four clauses in the supply agreement:
- An agreed specification that names the analytical method, the sampling plan and the tolerance for each parameter.
- An acceptance window, expressed in days from arrival, after which the batch is deemed accepted.
- A referee laboratory clause naming an independent third lab and stating that its result binds both parties.
- A cost allocation clause covering storage, retesting, destruction and any return freight.
Without an acceptance window, a buyer can hold a claim open for months while the market price moves. Without a referee clause, every disagreement escalates to a commercial negotiation in which the party holding the goods has the stronger hand.
Three ways a rejected batch ends
Once the importer issues a formal rejection, the batch resolves in one of three ways. The table below sets out what each route typically involves.
| Route | Typical timeline | Approvals involved | Where the cost lands |
|---|---|---|---|
| Investigate and re-release | 3 to 8 weeks | Importer and QP decision, referee lab result | Testing, storage, delayed revenue |
| Destroy in destination market | 2 to 6 weeks | Destination narcotics authority, witnessed destruction record | Full loss of goods, destruction fee |
| Return to Canada | Months, approval uncertain | Destination export authorisation plus a Health Canada import permit | Freight both ways, permit fees, quarantine on arrival |
Investigate and re-release
Start here whenever the result is contestable. Pull your retention sample, run it against the importer's stated method, and ask for the destination laboratory's raw data rather than a summary certificate. Where the finding is genuine and the destination market permits remediation, treatment may bring a microbial result back inside limits, though acceptance varies by market and by buyer. Document the root cause and the corrective action either way, because the next purchase order depends on that file more than on this batch.
Destroy in the destination market
Destruction is often the commercially rational choice for a low-value lot. It's handled under the destination country's narcotics and medicines rules, usually with witnessed destruction and a certificate issued to the importer. Insist on receiving a copy of that record for your own batch documentation, and reconcile the destroyed quantity in your reporting so your inventory position stays defensible at your next Health Canada inspection.
Return to Canada
Bringing cannabis back into Canada is an import, with everything that implies. You need a Health Canada import permit for that specific shipment under Part 10 of the Cannabis Regulations. The application fee is $610, and the department works to a service standard of 30 business days from payment to decision. Health Canada's stated general policy is to issue import permits only in limited circumstances, such as starting material for a new licence holder or small quantities for scientific purposes. A commercial return doesn't sit neatly inside either example, so plan on the assumption that approval is uncertain rather than routine. The destination authority also has to authorise the outbound movement, and returned goods arrive in Canada in quarantine status, not as saleable inventory.
One point that surprises first-time exporters: a rejection at in-market release is not a recall, and it doesn't by itself trigger recall reporting. If the batch had already been distributed, different duties apply, which we cover in our guide to recall requirements for Canadian LP exporters.
The four-point pre-shipment release check
Rejections are cheaper to prevent than to resolve, and the prevention work is unglamorous. Run these four checks before a pallet leaves the facility.
- Specify to the destination, not to Canada. Map your release panel against the limits and methods the destination applies, and close the gaps before harvest allocation rather than after packing.
- Retest a retained sample against the buyer's method. Agree the method, the sampling plan and the referee laboratory in writing, then confirm your own result under those conditions before you ship.
- Ship the documentation as one reconciled package: COA, batch record summary, cultivation and manufacturing evidence, permit copies and labelling proofs, with a single batch identifier that matches on every page.
- Confirm the permit and quota position at the destination. Germany's import approvals are tied to annual narcotics estimates, and Australian importers need an Office of Drug Control licence plus a per-consignment permit. A batch that is compliant but unpermitted still doesn't move.
Buyers read that package as a proxy for how you run the facility. A file that reconciles on the first pass tells a quality manager the batch behind it was made the same way.
AlphaLeaf is a Health Canada Licensed Producer based in Montreal, growing indoor, hand-trimmed flower from refined genetics. We hold export authorisation under the Cannabis Act, and every batch ships with ISO-certified laboratory testing, full traceability and documentation built for the destination market. Our partners supply the German, Australian and Israeli medical channels.
If you're evaluating a Canadian supply partner and want to see how a release file is assembled before you commit to a first order, talk to the AlphaLeaf team.
Frequently Asked Questions
What is a rejected cannabis consignment?
A rejected cannabis consignment is a batch that has cleared customs in the destination country and then failed the importer's release testing or documentation review. The product stays in a licensed warehouse in that market and cannot be sold until the parties agree on retesting, destruction or return.
Can a Canadian Licensed Producer get a rejected batch back from Germany?
Sometimes, but it is not routine. The destination authority must authorise the outbound movement, and Health Canada must issue an import permit for the shipment under Part 10 of the Cannabis Regulations. Health Canada's stated general policy is to issue import permits only in limited circumstances, so a commercial return should be treated as uncertain rather than guaranteed.
Who pays when an importer rejects a cannabis batch?
The supply agreement decides. Incoterms allocate risk in transit, not conformity, so the answer depends on the agreed specification, the acceptance window, the referee laboratory clause and the cost allocation clause. Where those terms are missing, the party holding the goods usually has the stronger negotiating position.
How is a batch rejection different from a recall?
A rejection happens at in-market release, before the product reaches pharmacies or patients, and it is primarily a contractual matter between supplier and importer. A recall applies to product already distributed and carries reporting duties under the Cannabis Act and the rules of the destination market.
Can a failed batch be retested and released?
Yes, where the original result is contestable or the failure can be remediated in a way the destination market accepts. Pull the retention sample, retest against the importer's stated method, request the destination laboratory's raw data, and document root cause and corrective action regardless of the outcome.
How long does a Health Canada import permit take?
Health Canada applies a non-binding service standard of 30 business days from the date payment is received to the date a decision is issued. The application fee for a cannabis import or export permit is $610, and a separate permit is required for each individual shipment.
